Audio is streamed directly from the publisher (chtbl.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Clinical research treating mental illness with psychedelics has been ongoing for decades, but now there's a group of companies exclusively focused on using LSD and other psychedelics to treat mental health disorders.
Dan digs into the argument for legalizing prescription psychedelics, and the treacherous FDA approval path, with MindMed CEO JR Rahn, whose company recently listed on the Nasdaq.